Keywords
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Health Assessment Questionnaire Score
- Etanercept Group
- Curr Opin Investig Drug
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Moreland LW, Schiff MD, Baumgartner SW, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6): 478–486.
Weinblatt ME, Kremer JM, Bankhurst AD, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4): 253–259.
Maini R, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monocolonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.
Maini R, St. Clair EW, Breedveld F, et al. (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 354: 1932–1939.
Lipsky PE, van der Heijde DM, St. Clair EW, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594–1602.
Bathon JM, Martin RW, Fleischmann RM, et al. (2000) A comparison of etancercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22): 1586–1593.
Genovese MD, Bathon JM, Martin RW, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis; two-year radiographic and clinical outcomes. Arthritis Rheum 46(6): 1443–1450.
Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25(8): 1544–1552.
Danning CL, Illei GG, Hitchon C, et al. (2000) Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43: 1244–1256.
Mizutani H, Ohmoto Y, Mizutani T, et al. (1997) Role of increased production of monocytes TNF-α, IL-1β and Il-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14: 145–153.
Partsch F, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24: 518–523.
Bonifati C, Ameglio F (1999) Cytokines in psoriasis. Int J Dermatol 101: 783–794.
Ettehadi P, Greaves NW, Wallach D, et al. (1994) Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146–151.
Mussi A, Bonifati C, Carucci M, et al. (1997) Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11: 115–118.
Chodorowska G (1998) Plasma Concentrations of IFN-γ and TNF-α in psoriatic patients before an after local treatment with dithranol ointment. J Eur Acad Dermatol Venerol 10: 147–151
Wakefield PE, James WD, Samlaska CP (1991) Tumor necrosis factor. J Am Acad Dermatol 24: 675–685.
Feldmann M, Brennan FM, Maini RN (1995) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397–440.
Terajima S, Higaki M, Igarashi Y, et al. (1998) An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 290: 246–252.
Barnes PJ, Karin M (1997) Nuclear factor-kappaB A pivotal transcription factor in chronic inflammatory diseases. NEJM 336: 1066–1072.
Saklatvala J (1986) Tumor necrosis factor alpha stimulates resoption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547–549.
Bertolini DR, Nedwin GE, Bringman TS, et al. (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319: 516–518.
Shinmei M, Masuda K, Kikuchi T, Shimomura Y (1989) The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 6(suppl 18): 32–34.
Dayer JM, Beutler B, Cerami A (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168.
Ritchlin C (2003) Mechanisims of TNF-alpha and RANKL mediated osteoclastogenesis and bone resoption in psoriatic arthritis. Journal of Clin Invest 111(6): 821–831.
Nickoloff BJ (1999) The immunologic and genetic basis of psoriasis. Arch Dermatol 135: 1104–1110.
Mease PJ. Psoriatic Arthritis/Psoriasis. ch.32 in Smolen JS, Lipsky PE (eds.) Targeted Therapies in Rheumatology. Martin Dunitz, London, 2003.
Mease PJ (2003) Current treatment of psoriatic arthritis. Rheum Dis Clin N Am 29: 495–511.
Mease PJ (2003) Recent advances in the treatment of psoriatic arthritis. Current Opinion in Rheumatology 15(3): 205–212.
Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390.
Clegg DO, Reda DJ, Weisman MH, et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2013–2020.
Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scale. J Rheumatol 9: 789–793.
Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157: 238–244.
Mease PJ, Goffe BS, Metz J, et al. (2001) Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis. Ann Rheum Dis 60(Suppl 1): 146.
Mease P, Kivitz A, Burch F, et al. (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50: 2264–2272.
Mease P, Ganguly L, Wanke E, et al. (2004) How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome meausres in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 63(Suppl 1): 391.
Kosinski M, Keller SD, Ware JE Jr, Hatoum HT, Kong SX (1999) The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 37(Suppl 5): MS23–39.
Bukhari M, Wiles NJ, Lunt M, et al. (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48: 21–34.
Strand V, Sharp JT (2003) Radiographic data from recent randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 48: 21–34.
Emery P (2002) Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol 66: 3–8.
Landewé R (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48: 1–5.
Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D (1998) Radiological assessment in psoriatic arthritis. Br J Rheumatol 37: 760–765.
Ory P, Sharp J, Salonen, D, et al. (2002) Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum 46(Suppl 9): S196.
Sharp JT, Young DY, Bluhm GB, et al. (1985) How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28: 1326–1335.
FDA Briefing Document for the March 4, 2003 meeting of the Arthritis Advisory Committee: Update on the TNF-Blocking Agents. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing.pdf. Accessed October 31, 2003. 2003.
Antoni C, Dechant C, Hanns-Martin Lorez PD, et al. (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imagine measurements of reduction of inflammation. Arthritis Rheum 47(5): 506–512.
Van den Bosch F, Kruithof E, Baeten D, et al. (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46(3): 755–765.
Kruithof E, Van den Bosch F, Baeten D, et al. (2002) Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61(3): 207–212.
Antoni CE, Kavanaugh A, Kirkham B, et al. (2002) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arth Rheum 46(Suppl 9): S381.
Antoni C, Kavanaugh A, Kirkham B, et al. (2005) The infliximab multinational psoriatic arhtritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum (in press), (IMPACT)
Antoni CE, Kavanaugh A, Kirkham B, et al. (2003) The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arth Rheum 48(Suppl 9): S265.
Antoni C, Kavanaugh A, Gladman DD, et al. (2004) The Infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum 50(Suppl 9): S450.
Kavanaugh A, Krueger G, De Vlam K, et al. (2004) Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT 2 trial. Arthritis Rheum 50(Suppl 9): S617.
Mease P, Kavanaugh A, Krueger G, et al. (2004) Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from the IMPACT 2 trial. Arthritis Rheum 50(Suppl 9): S616.
Weinblatt ME, Keystone EC, Furst DE, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1): 35–45.
van de Putte LB, Atkins C, Malaise M, Sany J, et al. (2003) Monotherapy in the Treatment of Patients with Severely Active Rheumatoid Arthritis. Arthritis Rheum 46(suppl 9): S205.
Furst DE, Schiff MH, Fleischmann RM, et al. (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 30(12): 2563–2571.
Keystone E, Haraoui B. (2004) Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 30(2): 349–364.
Ritchlin C, Anandarajaha A, Totterman S, et al. (2004) Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis. Ann Rheum Dis 63(Suppl 1): 403.
Mease P, Gladman DD, Ritchlin C, et al. (2004) Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 50: 4097.
Nikas SN, Drosos AA (2003) Onercept. Serono. Curr Opin Investig Drugs 4(11): 1369–1376.
Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63(7): 755–758.
Tak P-P, Kraan MC, Goedkoop AY, et al. (2003) Early effects of infliximab therapy on inflammatory cells in lesional epidermis and synovial tissue if patients with psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 339.
Tak P-P, Kraan MC, Goedkoop AY, et al. (2003) Infliximab reduces the expression of adhesion molecules in skin and synovial tissue of patients with psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 605.
Veale DJ, Markham T, Fearon U, et al. (2003) Anti-TNF alpha therapy in psoriasis and psoriatic arthritis: clinical and angiogenic responses [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 341.
Canete JD, Sanmarti R, Marsal S, et al. (2003) Antiangiogenic effects of infliximab in synovial tissue in psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 1): Abstract 345.
Kruithof E, Baeten D, Van den Bosch F, et al. (2003) Down-regulation of synovial inflammation by TNF alpha blockade with infliximab in spondyloarthropathy: a histopathological study in 20 patients [abstract]. Ann Rheum Dis 62(Suppl 1): Abstract AB0370.
Devos SA, Van Den BN, De Vos M, Naeyaert JM (2003) Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206(4): 388–390.
Cheifetz A, Smedley M, Martin S, et al. (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98(6): 1315–1324.
Remicade® (infliximab) prescribing information. Malvern, Pa: Centocor, Inc, 2003.
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9): 2287–2293.
Garcia I, Miyazaki Y, Araki K, et al. (1995) Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol 25(8): 2401–2407.
Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.
Mohan VP, Scanga CA, Yu K, et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69(3): 1847–1855.
Ruderman EM, Markenson JA. (2003) Granulomatous infections and tumor necrosis factor antagonist therapies: update through June 2002. Arth Rheum 48(Suppl 9): S241.
Keane J, Gershon S, Wise RP, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15): 1098–1104.
Furst DE, Breedveld FC, Kalden JR, et al. (2004). Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63Suppl 2: ii2–ii12.
Beauparlant P, Papp K, Haraoui B (1999). The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29(3): 148–158.
Cush JJ, Kavanaugh AF. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part I: The risk of lymphoma with rheumatoid arthritis (RA) and TNF inhibitors. Available at: http://www.rheumatology.org/research/hotline/0303TNFL.htm.Accessed on October 24, 2003-2003.
Mohan N, Edwards ET, Cupps TR, et al. (2001) Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis Rheum 44(12): 2862–2869.
Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9): 1977–1983.
Enbrel® (Etanercept) prescribing information. Thousand Oaks, Calif: Immunex Corporation, 2003.
HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories, 2003.
Kavanaugh A, Keenan G, DeWoody K, et al. (2001) Long-term follow-up of patients treated with remicade (infliximab) in clinical trials. Arthritis Rheum 44: S81.
Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359(9306): 579–580.
Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9(3): 176–178.
Ali Y, Shah S (2002) Infliximab-induced systemic lupus erythematosus. Ann Intern Med 137(7): 625–626.
Debandt M, Vittecoq O, Descamps V, Le L, X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22(1): 56–61.
Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348: 601–608.
Mann DL, McMurray JJ, Packer M, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594–602.
Anker SD, Coats AJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86(2–3): 123–130.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25): 3133–3140.
Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10): 807–811.
Schiff M, Mease PJ, Weinblatt M, et al. (2000) Randomized controlled trial of 25 Mg vs. 50 Mg Enbrel (Etanercept) twice weekly in rheumatoid arthritis (RA). Arth Rheum 43(Suppl 9): S391.
Hansen KE, Cush JJ, Patel S, Genovese MC, Schiff M (2002) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. Arthritis Rheum 46:9 (Suppl): S538–A1439.
Haraoui PB, Keystone EC, Thorne JC, et al. (2003) The Canadian biologic observational switchover survey (BOSS): Switching from infliximab to etanercept leads to successful treatment of rheumatoid arthritis. Ann Rheum Dis. 62(Suppl 1): Abstract 226.
Bombardieri S, Tzioufas AG, McKenna F, et al. (2004) Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologics in the ReAct trial. Arthritis Rheum 50(Suppl 9): S187.
Genovese MC, Cohen S, Moreland L, et al. (2003) A randomized double-blind controlled study evaluating the safety and efficacy of etanercept vs etanercept plus ankinra in patients with rheumatoid arthritis. Ann Rheum Dis 62(Suppl 1): 66.
References
Bulbul R, Williams WV, Schumacher HR Jr (1995) Psoriatic arthritis. Diverse and sometimes highly destructive. Postgrad Med 97: 97–96, 103–106, 108
Mease P (2003) Psoriatic arthritis/psoriasis. In: Smolen J, Lipsky P (eds) Targeted therapies in rheumatology. Martin Dunitz, London, pp 525–548
Pipitone N, Kingsley GH, Manzo A, et al. (2003) Current concept and new developments in the treatment of psoriatic arthritis. Rheumatology 42: 1138–1148
Antoni C, Kavanaugh A, Kirkham B, et al. (2003) The one-year results of the infliximab multinational psoriatic arthritis controlled trial. Arthritis Rheum 48: S604
Braun J, Sieper J (2000) Anti-TNF alpha: a new dimension in the pharmacotherapy of the spondyloarthropathies? Ann Rheum Dis 59: 404–407
Braun J, Sieper J (2003) Role of novel biological therapies in psoriatic arthritis. Biodrugs 17: 187–199
Mease PJ, Goffe BS, Metz J, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390
Panayi G (1994) Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 8: 419–427
Utset TO, Auger JA, Peace D, et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907–1913
Costello PJ, Winchester RJ, Curran SA, et al. (2001) Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol 166: 2878–2886
Laloux L, Voisin MC, Allain J, et al. (2001) Immnohistological study of enthesis in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60: 316–321
Tassiulas I, Duncan SR, Centola M, et al. (1999) Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 60: 479–491
Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544–1552
Partsch G, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24: 518–523
Giustizieri ML, Mascia F, Frezzolini A, et al. (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-driven cytokines. J Allergy Clin Immunol 107: 871–877
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–916
Duan H, Koga T, Kohda F, et al. (2001) Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 26: 119–124
Gottlieb AB (2001) Psoriasis: immunopathology and immuno-modulation. Dermatol Clin 19: 649–657
Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34: 1–5
Bresnihan B, Cunnane G (1998) Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 24: 615–628
Dinarello CA (1998) Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 856: 1–11
Gabay C (2003) IL-1 trap. Regeneron/Novartis. Curr Opin Investig Drugs 4: 593–597
Krueger J, Ray A, Tamm I, et al. (1991) Expression and function of interleukin-6 in epithelial cells. J Cell Biochem 45: 327–334
Nurieva RI, Treuting P, Duong J, et al. (2003) Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 111: 701–706
Plater-Zyberk C, Joosten LA, Helsen MM, et al. (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108: 1825–1832
Barker JN, Jones ML, Mitra RS, et al. (1991) Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 139: 869–876
Singri P, West DP, Gordon KB (2002) Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 138: 657–663
Asadullah K, Sterry W, Stephanek K, et al. (1998) IL-10 is a key cytokine in psoriasis. J Clin Invest 101: 783–794
Reich K, Garbe C, Blaschke V, et al. (2001) Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 116: 319–329
Asadullah K, Friedrich M, Hanneken S, et al. (2001) Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 116: 721–727
McInnes IB, Illei GG, Danning CL, et al. (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167: 4075–4082
Leng SX, Elias JA (1997) Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 159: 2161–2168
Trepicchio WL, Bozza M, Pedneault G, et al. (1996) Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157: 3627–3634
Yawalkar N, Karlen S, Hunger R, et al. (1998) Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111: 1053–1057
Trepicchio WL, Ozawa M, Walters IB, et al. (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104: 1527–1537
Krueger JG, Walters IB, Miyazawa M, et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448–458
Weinberg JM (2003) An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 25: 2487–2505
Weinberg JM, Tutrone WD (2003) Biologic therapy for psoriasis: the T cell-targeted therapies — Efalizumab and Alefacept. Cutis 71: 41–45
Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345: 248–255
Kraan MC, van Kuijk AWR, Dinant HJ, et al. (2002) Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46: 2776–2784
Lebwohl M, Tyring SK, Hamilton TK, et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004–2013
Gottlieb AB, Krueger JG, Wittkowski K, et al. (2002) Psoriasis as a model for T cell mediated disease: immunobiologic and clinical effects of treatment of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138: 591–600
Abrams JR, Kelley SL, Hayes E, et al. (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192: 681–693
Nakahara H, Song J, Sugimoto M, et al. (2003) Antiinterleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521–1529
Fierlbeck G, Rassner G (1990) Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 95(Suppl 6)138S–141S
O’Connell PG, et al. (1992) Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 19: 80–82
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2005). B Psoriatic Arthritis. In: Gordon, K.B., Ruderman, E.M. (eds) Psoriasis and Psoriatic Arthritis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27190-2_19
Download citation
DOI: https://doi.org/10.1007/3-540-27190-2_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21280-5
Online ISBN: 978-3-540-27190-1
eBook Packages: MedicineMedicine (R0)